Overview

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

Status:
Active, not recruiting

Trial end date:
2026-07-15

Target enrollment:

Participant gender:

Summary

This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Acerta Pharma BV

Treatments:

Acalabrutinib